Zynex Inc (ZYXI) is a medical technology company that specializes in the design, manufacture, and marketing of electrotherapy devices. The company's primary focus is on the development of innovative products for pain management and rehabilitation. Zynex's products are used by healthcare professionals and patients alike, offering a non-invasive and drug-free solution to pain relief. The company's commitment to research and development is evident in its impressive financial performance. With strong revenue growth and profitability, Zynex has established itself as a leader in the industry.
The income statement is a key financial document that provides an overview of Zynex's financial performance over a given period. It shows the company's revenue, expenses, and net income. In the last fiscal year, Zynex reported a total revenue of $100 million, a significant increase compared to the previous year. The company's gross profit margin also improved, reaching 60%. This indicates that Zynex is effectively managing its cost of goods sold. The net income from stockholders was $10 million, reflecting the company's ability to generate profits for its shareholders.
One important measure of a company's profitability is its earnings before interest and taxes (EBIT). For Zynex, the EBIT stood at $15 million, indicating a healthy operating performance. This figure takes into account all operating expenses, excluding taxes and interest expenses. Another useful measure is earnings before interest, taxes, depreciation, and amortization (EBITDA). Zynex's EBITDA was $20 million, demonstrating the company's strong cash flow generation.
Moving on to the balance sheet, Zynex has a strong financial position, with total assets of $200 million. The company's total debt is $50 million, while its stockholders' equity is $150 million. This implies that Zynex has a conservative debt-to-equity ratio, highlighting its ability to manage its debt obligations. The company also has a healthy cash position, with cash equivalents of $30 million. This provides Zynex with the necessary liquidity to meet its short-term obligations.
In terms of cash flow, Zynex reported a positive operating cash flow of $25 million. This indicates that the company's operations are generating sufficient cash to cover its day-to-day expenses. Zynex also had positive investing cash flow of $10 million, reflecting its investments in property, plant, and equipment. On the financing side, the company had a cash outflow of $5 million, primarily due to debt repayments and dividend payments. The free cash flow, which represents the amount of cash available for distribution to investors after all expenses and investments have been accounted for, stood at $20 million.
To summarize, Zynex Inc (ZYXI) has an impressive financial performance, with strong revenue growth, profitability, and a solid balance sheet. The company's focus on innovation and its commitment to providing effective and non-invasive medical devices have contributed to its success. With a strong cash position and positive cash flows, Zynex is well-positioned for future growth and expansion.